diaTribe®

18/07/2025

Here are 6 things you can try to make sure that your CGM is working for you, and helping you live your best life with diabetes tech 💡

Receive more tips and tricks like this straight to your inbox at https://bit.ly/4iaYhDR.

11/07/2025

Have you saved the date? 📆

The Global Summit to is March 28-29, 2026 in Jaipur, India 🌏

You can learn more about what's in store and how to get involved at the link in our bio!

09/07/2025

It’s summer, so we thought we’d have a little fun. Check your zodiac sign to see what diabetes must-have you are 🔮✨ Check your sun, moon, and rising!

Whether you’re a low snack, one of our favorite metrics, or an accessory, we hope you feel empowered and ready to take on whatever this summer is bringing you.

Visit https://bit.ly/43PZIlm for diabetes tricks, tips, and so much more.

03/07/2025

Is now the time to expand the benefits of GLP-1 medications for people with type 1?

These new study results indicate that it is…in a new study presented at , Dr. Viral Shah and his team found that using GLP-1s and AID in people with type 1 diabetes can increase time in range!

Read more at https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500173.

Studies like these push forward innovation for people with diabetes—and we’re thrilled to see it!

27/06/2025

At American Diabetes Association – DiabetesPro (ADA) 2025, researchers explained how combining newer drugs like (GLP-1s and SGLT2s) and can lower requirements, optimize automated insulin delivery (AID) systems, and protect heart and kidney health.

They also outlined the risks – such as severe high and low blood sugar – and provided evidence-based guidance on how to avoid them. Although these therapies are U.S. Food and Drug Administration-approved only for type 2 diabetes, studies suggest 30% or more of people with type 1 use them off-label. Research also suggests that these drugs can cut insulin needs by half in those using AID systems, though it requires careful, frequent adjustments of insulin dosing and pump settings.

At least two clinical trials are being conducted testing GLP-1 drugs in people with type 1. Experts added that studies of people with type 1 using SGLT2 therapies are unlikely to occur until continuous ketone monitoring is available. A number of AID system makers – including Tandem Diabetes Care, Beta Bionics, and Sequel Medical Technology – have recently announced integrating with Abbott's future continuous glucose-ketone sensor.

Read more here: https://socx.ly/w5fqte

6 Minute Read

26/06/2025

🧬 Vertex Releases New Data on Potential Cure for Type 1

New study results showed that stem cell islet transplants provided the first sustained insulin production in a group of people with type 1 diabetes.

In a clinical trial, 12 participants who received a full dose of the Vertex therapy, called zimislecel (VX-880), no longer required daily insulin after one year, although all continued to require ongoing immunosuppressive therapy. Ten participants saw significantly improved glucose levels, spending more than 90% of the time in range. Two other full-dose participants showed signs of insulin production and spent more than 70% of the time in range, but still required some insulin.

Before receiving the treatment, all participants had hypoglycemia unawareness and experienced multiple severe low blood sugar events in the previous year. After treatment, none of these events were reported.

Read more here: https://bit.ly/4nfNvz6

💡WHY IT MATTERS

Though early, the results represent a potential breakthrough toward a functional cure. Larger, longer-term studies are planned to evaluate the safety and durability of the approach. An ongoing clinical trial is expected to complete enrollment of 50 participants this summer.

Source: FierceBiotech

diaTribe is a non-profit organization providing free cutting-edge diabetes management tips from diet and exercise, to ways to avoid diabetes complications.

26/06/2025

🚨 AID use in people with type 2 diabetes increases time in range! 🚨

We just got back from and were thrilled to see new data on how AID (automated insulin delivery) systems are helping people with type 2 diabetes increase their time in range—which is huge news!

AID and time in range are tools that have been shown to help people with diabetes thrive. We love that access to these tools are expanding, and we can’t wait to see more!

Read more about type 2 diabetes and AID research at https://diatribe.org/diabetes-management/could-aid-transform-type-2-diabetes-care.

25/06/2025

People with type 2 and peripheral arterial disease ( ) saw a 21% increase in how far they could walk, without being in pain, after taking semaglutide (Ozempic® (semaglutide) injection 0.5 mg, 1 mg, 2 mg), according to new research presented at American Diabetes Association – DiabetesPro (ADA) 2025.

The study followed 792 participants over a year and found that they were able to walk 40 more meters, approximately 131 feet. Semaglutide also cut the combined risk of death or emergency artery surgery by 54%.

This suggests that the benefits of semaglutide extend to people with type 2 diabetes and PAD, helping them to walk without pain in everyday activities. Researchers pointed out the need to screen for PAD, which affects more than 230 million people worldwide, and leads to lower quality of life and a higher risk of serious heart complications.

Read more here: https://bit.ly/46bDwEX

14 Minute Read

24/06/2025

A few months ago, the American Diabetes Association (ADA)’s Association published two chapters of the first-ever Standards of Care in and Obesity. Presenting at the 2025 American Diabetes Association – DiabetesPro (ADA) Scientific Sessions, experts highlighted the importance of addressing and , while also discussing the focus of future chapters – including recommendations for treating obesity.

The chapter on weight bias and stigma focuses its recommendations on improving education and training, the clinical environment and practice, and communication and collaboration between healthcare professionals and those living with obesity.

Future chapters, published in the coming months, will provide guidance on obesity treatments. Currently, obesity is massively underdiagnosed and rarely treated – one recent white paper showed that only 2% of individuals living with overweight or obesity actually receive a prescription for a GLP-1. Because of data like this, the Standards aim to focus on delivering recommendations that address person-centered care, treatment goals, medication recommendations, and when to introduce nutrition and behavioral interventions.

Read more here: https://bit.ly/4ljxuX1

9 Minute Read

23/06/2025

Vertex Releases New Data on Potential Cure for Type 1

At ADA 2025 (American Diabetes Association – DiabetesPro), Vertex shared results of a study that showed stem cell islet transplants provided the first-ever sustained insulin production in a group of people with type 1 diabetes.

In an ongoing clinical trial, 12 participants who received a full dose of the Vertex therapy, called zimislecel (VX-880), no longer required daily insulin after one year, although all continued to require ongoing immunosuppressive therapy. Ten participants saw significantly improved glucose levels, spending more than 90% of the time in range. Two other full-dose participants showed signs of insulin production and spent more than 70% of the time in range, but still required some insulin.

Before receiving the treatment, all participants had hypoglycemia unawareness and experienced multiple severe low blood sugar events in the previous year. After treatment, none of these events were reported. Though early, the results represent a potential breakthrough toward a functional cure.

Read more here: https://bit.ly/4nkQeaO

8 Minute Read

22/06/2025

Researchers are studying an endoscopic intestinal (ReCET) that treats the lining of the upper small intestine to see if it improves blood sugar management in individuals with type 2 .

Visit https://bit.ly/3FXRX4W to learn or or see if you're eligible to participate.

3 Minute Read

20/06/2025

📱 CGM Reduces Mortality Risk for Insulin-Dependent Type 2 Diabetes

It’s known that continuous glucose monitoring (CGM) can improve blood sugar management, but it has been unclear whether these benefits also reduce the risk of life-threatening health problems.

A recent study of people with insulin-dependent type 2 diabetes found that starting CGM was linked to a 21% lower risk of death. New CGM users also had fewer hospitalizations, cardiovascular events, and episodes of dangerously high blood sugar.

Read more here: https://bit.ly/45rup2E

💡WHY IT MATTERS

CGM may offer more than just better blood sugar management – these devices could be life-saving tools for those managing insulin-dependent type 2 diabetes.

Source: Diabetes Technology & Therapeutics (Mary Ann Liebert, Inc., publishers)

Continuous glucose monitors show real-time glucose values, replacing the need for fingersticks.